Clinical trialNCT05238597CompletedPhase 2Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

SponsorAramis Biosciences, Inc.Enrollment207Dry Eye Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The objectives of this trial are to assess the safety, tolerability and efficacy of A197 ophthalmic solution in comparison to a vehicle control in the treatment of subjects with Dry Eye Disease.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

David S Tierney, MD
Aramis Biosciences
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Aramis Site 113
Birmingham, Alabama, United States
Aramis Site 121
Garden Grove, California, United States
Aramis Site 120
Glendale, California, United States
Aramis Site 106
Long Beach, California, United States
Aramis Site 124
Los Angeles, California, United States
Aramis Site 107
Murrieta, California, United States
Aramis Site 102
Newport Beach, California, United States
Aramis Site 116
Petaluma, California, United States
Aramis Site 109
Rancho Cordova, California, United States
Aramis Site 101
Delray Beach, Florida, United States
Aramis Site 112
Jacksonville, Florida, United States
Aramis Site 117
Largo, Florida, United States
Aramis Site 118
Edgewood, Kentucky, United States
Aramis Site 114
Kansas City, Missouri, United States
Aramis Site 111
St Louis, Missouri, United States
Aramis Site 108
Las Vegas, Nevada, United States
Aramis Site 110
Garner, North Carolina, United States
Aramis Site 122
Shelby, North Carolina, United States
Aramis Site 119
Mason, Ohio, United States
Aramis Site 123
Cranberry Township, Pennsylvania, United States
Aramis Site 115
Goodlettsville, Tennessee, United States
Aramis Site 103
Memphis, Tennessee, United States
Aramis Site 104
Lakeway, Texas, United States
Aramis Site 105
San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

A197 Ophthalmic SolutionA197 Vehicle ControlActive Comparator

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 25 Jan 2022
Primary completion: 24 Jan 2023
Completion: 24 Jan 2023
Last update posted: 16 May 2023
Registered enrollment: 207
Registry id: NCT05238597

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.